

| | |
|-----------------------------|--|
| Name and institution | <p>apl Prof Dr Oleg Timofeev Philipps-Universität Marburg Institut für Molekulare Onkologie Zentrum für Tumor- und Immunbiologie (ZTI) Hans-Meerwein-Str. 3, 35043 Marburg Tel.:+49(0)06421-28-26288 Fax:+49(0)6421-28-24292 E-Mail: timofeev@staff.uni-marburg.de Web: https://www.uni-marburg.de/en/fb20/departments/zti/imo/staff/timofeev ORCID 0000-0002-3114-6403</p> |
| Position | Research scientist, Group leader |
| Date of Birth | 06.09.1969 |
| Academic career | |
| 11/2022 | Professor (apl) at the Philipps-University of Marburg |
| 6/2016 | Habilitation at the Philipps-University of Marburg for Molecular Oncology |
| 8/2010- | Senior Post-doc, Group leader at the Institute of Molecular Oncology, Philipps-University of Marburg |
| 11/2008 – 06/2010 | Project coordinator, R&D department, Alkor-Bio Group, St.Petersburg, Russia |
| 08/2005 – 11/2008 | Post-doc at the Cell Cycle Control and Carcinogenesis group, German Cancer Research Centre, Heidelberg |
| 03/2004 – 02/2005 | Guest Scientist, Cell Cycle regulation and Tumorigenesis group, Institute of Molecular and Cell Biology, Singapore |
| 06/2003 – 12/2003 | Guest Scientist, Basic Research Laboratory, National Cancer Institute, NIH, Bethesda, USA |
| 02/2002 – 08/2002 | Practical student (grantee), Institute of Molecular Biology, Center for Cancer Research and Cancer Therapy, University of Essen |
| 10/2000 – 11/2002 | Scientific assistant, Department of Molecular Mecanisms of Cell Differentiation, Institute of Cytology, Russian Academy of Sciences, St.-Petersburg, Russia |
| Academic degrees | |
| 11/2022 | Professor (apl) at the Philipps-University of Marburg |
| 10/2016 | Privat-Dozent, Philipps-University of Marburg, Habilitation Thesis “Stress-induced pathways in tumor suppression” |
| 03/2005 | Kandidat Nauk (Candidate of Science, Russian equivalent of PhD), Institute of Cytology of Russian Academy of Science (St. Petersburg, Russia), Thesis: “The role of p38 MAPK and Wip1 phosphatase in tumor suppression and tumorigenesis” |
| University education | |
| 06/2000 – 10/2002 | MSc, St. Petersburg State University (St. Petersburg, Russia) |

05/2000

BSc, St. Petersburg State University

5/1992 – 5/2000

Study of Biology and Informatics at the St. Petersburg State University and St. Petersburg Industrial College

Selected publications (last 5 years)

1. Merle N, Bullwinkel I, Timofeev O, Elmshäuser S, and Stiewe T “Secreted luciferases as a minimally invasive 3R-compliant tool for accurate in vivo monitoring of tumor burden” **Nature Protocols** 2025 (IF 16.0)
2. Dizdarević S, Timofeev O, Kazdal D, Pullamsetti S, Sotillo R, Loges S, Kobold S, Stenzinger A, Stiewe T, Savai R “Tumor microenvironment evaluation in lung cancer: Spatio-temporal dynamics and clinical implication” **Semin Cancer Biol** 2025 (IF 15.7)
3. Vaeyens F, Hetzel JP, Mernberger M, Eggermont C, Olsen C, Maes K, Vlaeminck J, Hes F, Pichler M, Giron P, Timofeev O*, Noeparast M “Variant-Specific Landscape of Mutual Exclusivity Among BRAF, EGFR, and KRAS Oncogenes in Human Cancer” **Int J of Cancer** 2025 *co-senior author (IF 4.7)
4. Timofeev O, Giron P, Lawo S, Pichler M, Noeparast M “ERK pathway agonism for cancer therapy: evidence, insights, and a target discovery framework” **NPJ Precis Oncol** (IF 8.0)
5. Noeparast M, Timofeev O, Pichler M “Enhancing oncogenic signaling to kill cancer cells” **Trends Pharmacol Sci** 2024 (IF 19.9)
6. Merle N, Elmshäuser S, Strassheimer F, Wanzel M, König AM, Funk J, Neumann M, Kochhan K, Helmprobst F, Pagenstecher A, Nist A, Mernberger M, Schneider A, Braun T, Borggrefe T, Savai R, Timofeev O, Stiewe T “Monitoring autochthonous lung tumors induced by somatic CRISPR gene editing in mice using a secreted luciferase” **Mol Cancer**. 2022 (IF 41.444)
7. Klimovich B, Meyer L, Merle N, Neumann M, König A, Ananikidis N, Keber C, Elmshäuser S, Timofeev O*, Stiewe T “Partial p53 reactivation is sufficient to induce cancer regression” **J of Experimental & Clinical Cancer Research** 2022 *co-senior author (IF 12.8)
8. Klimovich B, Merle N, Neumann M, Elmshäuser S, Nist A, Mernberger M, Kazdal D, Stenzinger A, Timofeev O*, Stiewe T. p53 Partial Loss-of-Function Mutations Sensitize to Chemotherapy. **Oncogene** 2021 *co- senior author (IF 8.64)
9. Timofeev O & Stiewe T “Rely on Each Other: DNA Binding Cooperativity Shapes p53 Functions in Tumor Suppression and Cancer Therapy” **Cancers** 2021 (IF 4.4)
10. Timofeev O “Mutant p53 in Cancer Progression and Personalized Therapeutic Treatments” **Front Oncol** 2021 (IF 4.84)
11. Klimovich B, Stiewe T, Timofeev O. Inactivation of Mdm2 restores apoptosis proficiency of cooperativity mutant p53 in vivo. **Cell Cycle** 2020 (IF 4.53)
12. Timofeev O, Koch L, Niederau C, Tscherne A, Schneikert J, Klimovich M, Elmshäuser S, Zeitlinger M, Mernberger M, Nist A, Osterburg C, Dotsch V, German Mouse Clinic C, Hrabe de Angelis M, and Stiewe T. (2020). Phosphorylation Control of p53 DNA-Binding Cooperativity Balances Tumorigenesis and Aging. **Cancer Res** 2020. (Highlighted by: Horikawa I. (2020). Balancing and Differentiating p53 Activities toward Longevity and No Cancer? **Cancer Res** 2020 (IF 12.70)
13. Gremke N, Polo P, Dort A, Schneikert J, Elmshäuser S, Brehm C, Klingmüller U, Schmitt A, Reinhardt HC, Timofeev O, Wanzel M, Stiewe T. „mTOR-mediated cancer drug resistance suppresses autophagy and generates a druggable metabolic vulnerability“ **Nat Commun** 2020 (IF 14.919)